Literature DB >> 15095331

Gas trapping in normal infants and in infants with cystic fibrosis.

Robert G Castile1, Durdana Iram, Karen S McCoy.   

Abstract

Two different methods for estimating trapped gas volume have been described in the literature. The purpose of this study was to use both of these methods to estimate and compare trapped gas volumes in normal infants and infants with cystic fibrosis (CF). Thirty normal infants and 29 infants with CF, ages 1 month to 3 years, were studied. Pulmonary function tests, including raised volume forced expiratory flows, plethysmographic functional residual capacity (FRC(pleth)), and fractional lung volumes, were measured. Then functional residual capacity was measured by nitrogen washout (FRC(nitrogen)). Following nitrogen washout, lungs were then inflated three times to 30 cm H(2)O, using 100% oxygen. This process was repeated until no further nitrogen could be washed from the lungs. The volume of trapped gas (tg) was calculated from the total additional amounts of nitrogen expired following lung inflations. The difference between FRC(pleth) and FRC(nitrogen) provided a second estimate of trapped gas volume (delta V). Mean tg and delta V values for normal infants were 2.5 +/- 3.5 ml and 15.6 +/- 30.4 ml, respectively. Mean tg and delta V values for infants with CF were 5.8 +/- 7.7 ml and 33.2 +/- 43.8 ml, respectively. Both tg and delta V did not differ significantly between normal infants and infants with CF. Measured following raised volume forced expiratory maneuvers, delta V and tg do not distinguish infants with CF from normal infants as well as do other currently available tests of infant lung function. Copyright 2004 Wiely-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15095331     DOI: 10.1002/ppul.10446

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  11 in total

1.  Computed tomography dose and variability of airway dimension measurements: how low can we go?

Authors:  Pim A de Jong; Frederick R Long; Yasutaka Nakano
Journal:  Pediatr Radiol       Date:  2006-08-10

2.  Multicenter evaluation of infant lung function tests as cystic fibrosis clinical trial endpoints.

Authors:  Stephanie D Davis; Margaret Rosenfeld; Gwendolyn S Kerby; Lyndia Brumback; Margaret H Kloster; James D Acton; Andrew A Colin; Carol K Conrad; Meeghan A Hart; Peter W Hiatt; Peter J Mogayzel; Robin C Johnson; Stephanie L Wilcox; Robert G Castile
Journal:  Am J Respir Crit Care Med       Date:  2010-07-09       Impact factor: 21.405

3.  Early pulmonary disease manifestations in cystic fibrosis mice.

Authors:  Rebecca J Darrah; Anna L Mitchell; Cara K Campanaro; Eric S Barbato; Paul Litman; Abdus Sattar; Craig A Hodges; Mitchell L Drumm; Frank J Jacono
Journal:  J Cyst Fibros       Date:  2016-05-24       Impact factor: 5.482

4.  Early detection of cystic fibrosis lung disease: multiple-breath washout versus raised volume tests.

Authors:  Sooky Lum; Per Gustafsson; Henrik Ljungberg; Georg Hülskamp; Andrew Bush; Siobhán B Carr; Rosemary Castle; Ah-Fong Hoo; John Price; Sarath Ranganathan; John Stroobant; Angie Wade; Colin Wallis; Hilary Wyatt; Janet Stocks
Journal:  Thorax       Date:  2006-11-22       Impact factor: 9.139

5.  A novel physiological investigation of the functional residual capacity by the bias flow nitrogen washout technique in infants.

Authors:  Mohy G Morris
Journal:  Pediatr Pulmonol       Date:  2009-07

6.  Comprehensive integrated spirometry using raised volume passive and forced expirations and multiple-breath nitrogen washout in infants.

Authors:  Mohy G Morris
Journal:  Respir Physiol Neurobiol       Date:  2009-11-06       Impact factor: 1.931

7.  Increased lung volume in infants and toddlers at high compared to low altitude.

Authors:  Conrado J Llapur; Myriam R Martínez; María Marta Caram; Federico Bonilla; Celia Cabana; Zhansheng Yu; Robert S Tepper
Journal:  Pediatr Pulmonol       Date:  2013-02-08

Review 8.  Endpoints for clinical trials in young children with cystic fibrosis.

Authors:  Stephanie D Davis; Alan S Brody; Mary J Emond; Lyndia C Brumback; Margaret Rosenfeld
Journal:  Proc Am Thorac Soc       Date:  2007-08-01

Review 9.  Novel end points for clinical trials in young children with cystic fibrosis.

Authors:  Shannon J Simpson; Lauren S Mott; Charles R Esther; Stephen M Stick; Graham L Hall
Journal:  Expert Rev Respir Med       Date:  2013-06       Impact factor: 3.772

10.  AGTR2 absence or antagonism prevents cystic fibrosis pulmonary manifestations.

Authors:  Rebecca J Darrah; Frank J Jacono; Neha Joshi; Anna L Mitchell; Abdus Sattar; Cara K Campanaro; Paul Litman; Jennifer Frey; David E Nethery; Eric S Barbato; Craig A Hodges; Harriet Corvol; Garry R Cutting; Michael R Knowles; Lisa J Strug; Mitchell L Drumm
Journal:  J Cyst Fibros       Date:  2018-06-22       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.